C Michael Gibson/Baim Institute
Feb 7, 2026, 14:25
C Michael Gibson: Asundexian Reduces Ischemic Stroke Without Increasing Bleeding Risk
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Among patients with non-cardioembolic ischemic stroke or high-risk TIA treated with antiplatelet therapy, asundexian 50 mg reduced the occurrence of ischemic stroke (csHR 0.74; 95% CI, 0.65 to 0.84; p<0.001).
The difference between the treatment arms began early and continued throughout the treatment period.
A consistent effect was seen in subgroups.
Asundexian was associated with a reduction in disabling or fatal stroke (mRS ≥ 3)
Asundexian was not associated with an increase in bleeding Including ISTH major, CRNM, minor or intracranial bleeding.”
Stay updated with Hemostasis Today.
-
Feb 7, 2026, 14:23Marco Antonio Ramírez Rodríguez: Endovascular Management of Pelvic Venous Hypertension in May–Thurner Syndrome
-
Feb 7, 2026, 14:19Martin Haluzík Analyzes the Overall Accuracy of Current Available Smartwatches in Identifying AF
-
Feb 7, 2026, 14:11Bhupesh Prusty: How Patient-Derived IgG Immune Complexes Directly Affect Human Cells
-
Feb 7, 2026, 14:05Samary Vazquez: Insights from My Hospital Bed – Guilt and Survival
-
Feb 7, 2026, 13:59Michael Ertl: Discussing Cerebral Vasospasm and Ultrasound Training at ANIM 2026
-
Feb 7, 2026, 13:56Roberta Gualtierotti: Productive Meeting on Joint Health in Hemophilia at EAHAD 2026
-
Feb 7, 2026, 13:52Tribeni Roy: Simple and Efficient Approach to Detect a Thrombus by Impedance Spectroscopy
-
Feb 7, 2026, 13:47Tagreed Alkaltham: Unsafe Behavior Is a Patient Safety Risk
-
Feb 7, 2026, 13:42Erin VanDyke: Chatting About All Things VTE With Trevor Cummings